Literature DB >> 8902733

Central pontine myelinolysis at autopsy; a twelve year retrospective analysis.

K L Newell1, B K Kleinschmidt-DeMasters.   

Abstract

Central pontine myelinolysis (CPM) was first described in 1959 and only later was associated with a rapid, sustained rise in serum sodium from a hyponatremic baseline. This discovery in 1981 led to modifications in recommendations for clinical treatment of hyponatremia. Our interest has been in tracking the incidence of CPM found at autopsy by year to see whether changes in medical treatment in hyponatremia have resulted in a decrease in CPM over time. Clinically asymptomatic CPM found at autopsy has always been at least as frequent as cases diagnosed premortem and serves as a reasonable indicator for the incidence of the disease. In over 3,000 autopsies, on most of which the brain was examined macroscopically and microscopically by the same neuropathologist, we have discovered 15 cases of asymptomatic, small pontine CPM. Of these 15, 6 were active lesions and 9 were remote; in the active group, 5 of the 6 cases were associated with a rapid, sustained rise in serum sodium during the appropriate time period. The incidence of asymptomatic CPM has remained steady over the 13-year time period. In contrast, we have encountered no cases of CPM diagnosed premortem that have come to autopsy in the same time period. These cases emphasize that CPM still occurs, but most often as an asymptomatic disorder with small, midline pontine lesions. When small active CPM is found, it still is associated with a rapid sustained rise in serum sodium.

Entities:  

Mesh:

Year:  1996        PMID: 8902733     DOI: 10.1016/0022-510x(96)00175-x

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  24 in total

1.  Osmotic demyelination syndrome.

Authors:  Rachel Abbott; Eli Silber; Joerg Felber; Enefiok Ekpo
Journal:  BMJ       Date:  2005-10-08

2.  Central pontine myelinolysis.

Authors:  Federica Fersini; Annamaria Govi; Michael Tsokos
Journal:  Forensic Sci Med Pathol       Date:  2014-11-14       Impact factor: 2.007

3.  Psychiatric symptoms and limb tremors associated with central pontine myelinolysis: A case of alcoholism without hyponatremia.

Authors:  Xue-Min Feng; Teng Zhao; Chun-Kui Zhou; Jing-Yao Liu
Journal:  Exp Ther Med       Date:  2016-10-04       Impact factor: 2.447

4.  A case of asymptomatic pontine myelinolysis.

Authors:  Angelica Lupato; Patrik Fazio; Enrico Fainardi; Edoardo Cesnik; Ilaria Casetta; Enrico Granieri
Journal:  Neurol Sci       Date:  2010-02-11       Impact factor: 3.307

5.  Clinical and radiologic correlations of central pontine myelinolysis syndrome.

Authors:  Jonathan Graff-Radford; Jennifer E Fugate; Timothy J Kaufmann; Jay N Mandrekar; Alejandro A Rabinstein
Journal:  Mayo Clin Proc       Date:  2011-10-13       Impact factor: 7.616

Review 6.  Preventing neurological complications from dysnatremias in children.

Authors:  Michael L Moritz; J Carlos Ayus
Journal:  Pediatr Nephrol       Date:  2005-08-04       Impact factor: 3.714

7.  Management of hyponatremia in various clinical situations.

Authors:  Michael L Moritz; Juan C Ayus
Journal:  Curr Treat Options Neurol       Date:  2014-09       Impact factor: 3.598

8.  Pontocerebellar volume deficits and ataxia in alcoholic men and women: no evidence for "telescoping".

Authors:  Edith V Sullivan; Torsten Rohlfing; Adolf Pfefferbaum
Journal:  Psychopharmacology (Berl)       Date:  2009-11-27       Impact factor: 4.530

9.  A case of late adult-onset dentatorubral-pallidoluysian atrophy mimicking central pontine myelinolysis.

Authors:  Junpei Kobayashi; Masahiro Nagao; Akihiro Kawata; Siro Matsubara
Journal:  J Neurol       Date:  2009-04-24       Impact factor: 4.849

10.  Central pontine and extrapontine myelinolysis despite careful correction of hyponatremia: clinical and neuropathological findings of a case.

Authors:  Vladimiro Pietrini; Flavio Mozzani; Pellegrino Crafa; Roberto Sivelli; Filippo Cademartiri; Girolamo Crisi
Journal:  Neurol Sci       Date:  2009-10-30       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.